Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Braz. dent. j ; 30(1): 43-46, Jan.-Feb. 2019. tab, graf
Article in English | LILACS | ID: biblio-989431

ABSTRACT

Abstract The aim of this study was to evaluate the effect of a lower dose of parathyroid hormone- PTH (1-34) on osteogenic potential of bone healing around titanium implants inserted into the tibia of rats. A blind parallel study was conducted in 45 adult male Wistar rats. Each rat received one titanium implant (4.5 x 2.2 mm) and was randomly assigned to receive subcutaneous injections, three times/week for 30 days, of the following treatments: group 1 - 40 µg/kg of PTH (1-34) (n=15); group 2 - 2 µg/kg of PTH (1-34) (n=15) and; group 3 - only the vehicle required for hormone dissolution (n=15). Thirty days after surgery, the animals were sacrificed and specimens containing the implant and the surrounding bone were removed and processed for non-decalcified sections. The sections were evaluated according to the following histometric parameters: proportion of mineralized tissue (PMT) adjacent to the implant threads (500 µm band); bone filling within the limits of the threads (BF) and; bone-to-implant contact (BIC). For the cortical region, both hormone dosages (groups 1 and 2) promoted better results, for all parameters, when compared to control group (p<0.05). Similar results were observed for the BF parameter in the cancellous region (p=0.0394). Therefore, systemic administration of PTH (1-34) stimulates bone formation around titanium implants, even at low doses.


Resumo O objetivo deste estudo foi avaliar o efeito de uma menor dose de PTH (1-34) sobre o potencial osteogênico da cicatrização óssea ao redor de implantes de titânio inseridos na tíbia de ratos. Um estudo paralelo cego foi conduzido em 45 ratos Wistar machos adultos. Cada rato recebeu um implante de titânio (4,5 x 2,2 mm) e foi aleatoriamente designado para receber injeções subcutâneas, três vezes / semana por 30 dias, dos seguintes tratamentos: grupo 1 - 40 µg/kg de PTH (1-34) (n = 15); grupo 2 - 2 µg/kg de PTH (1-34) (n = 15) e; grupo 3 - apenas o veículo necessário para a dissolução do hormônio (n = 15). Trinta dias após a cirurgia, os animais foram sacrificados e os espécimes contendo o implante e o osso ao redor foram removidos e processados ​​para cortes não descalcificados. As seções foram avaliadas de acordo com os seguintes parâmetros histométricos: proporção de tecido mineralizado (PTM) adjacente aos fios do implante (banda de 500 µm); preenchimento ósseo dentro dos limites dos fios (PO) e; contato osso-implante (COI). Para a região cortical, ambas as dosagens hormonais (grupos 1 e 2) promoveram melhores resultados, para todos os parâmetros, quando comparados ao grupo controle (p<0,05). Resultados semelhantes foram observados para o parâmetro PO na região esponjosa (p = 0,0394). Portanto, a administração sistêmica de PTH (1-34) estimula a formação óssea ao redor de implantes de titânio, mesmo em doses baixas.


Subject(s)
Animals , Male , Rats , Parathyroid Hormone/administration & dosage , Bone and Bones/drug effects , Dental Implants , Osseointegration , Rats, Wistar , Models, Animal , Dose-Response Relationship, Drug
2.
Actual. osteol ; 14(2): 125-147, Mayo - Ago. 2018. ilus, graf, tab
Article in Spanish | LILACS | ID: biblio-1116310

ABSTRACT

En consonancia con la orientación tradicional de nuestras investigaciones, la Osteología está incorporando progresivamente el análisis estructural-biomecánico óseo y las interacciones músculo-esqueléticas. En este artículo se sintetizan los aportes originales del CEMFoC a la Osteología moderna en el terreno biomecánico en forma didáctica, para que el lector aprecie sus posibles aplicaciones clínicas. Los hallazgos aportaron evidencias sucesivas en apoyo de dos proposiciones fundamentales: a) los huesos deben interpretarse como estructuras resistivas, biológicamente servocontroladas ("Los huesos tienden siempre a mantener un factor de seguridad que permite al cuerpo trabajar normalmente sin fracturarse" ­ Paradigma de Utah) y b) los huesos interactúan con su entorno mecánico, determinado principalmente por las contracciones musculares, en forma subordinada al entorno metabólico ("Los huesos son lo que los músculos quieren que sean, siempre que las hormonas lo permitan"). Los avances producidos se refieren, tanto cronológica como didácticamente, al conocimiento osteológico en general y al desarrollo de recursos novedosos para el diagnóstico no invasivo de fragilidad ósea, para distinguir entre osteopenias y osteoporosis, y para discriminar entre sus etiologías 'mecánica' y 'sistémica'. Finalmente, el nuevo conocimiento se integra en la proposición de un algoritmo diagnóstico para osteopenias y osteoporosis. El espíritu general de la presentación destaca que la evaluación osteomuscular dinámicamente integrada genera un nuevo espacio de análisis personalizado de los pacientes para la atención de cualquier osteopatía fragilizante con criterio biomecánico. (AU)


In consonance with the traditional spirit of our studies, skeletal research is being progressively focused on the structural-biomechanical analysis of bone and the muscle-bone interactions. In this article, the CEMFoC's members summarize their original findings in bone biomechanics and their potential clinical applications. These findings provided evidence supporting two fundamental hypotheses, namely, A. bones constitute resistive structures, which are biologically servo-controlled ('Bones tend to maintain a safety factor which allows the body to function normally avoiding fractures' ­ the 'Utah paradigm'), and B. the interactions of bones with their mechanical environment mainly are determined by the contraction of local muscles - 'bone-muscle units'), and are subordinated to the control of the metabolic environment ('Bones are what muscles wish them to be, provided that hormones allow for it'). The achievements in the field are presented in a chronological and didactical sequence concerning the general knowledge in Osteology and the development of novel resources for non-invasive diagnosis of bone fragility, aiming to distinguish between osteopenias and osteoporosis and the 'mechanical' and 'metabolic' etiology of these conditions. Finally, the integrated new knowledge is presented as supporting for a proposed diagnostic algorithm for osteopenias and osteoporosis. In general terms, the article highlights the dynamic evaluation of the musculoskeletal system as a whole, opening a new diagnostic field for a personalized evaluation of the patients affected by a boneweakening disease, based on functional and biomechanical criteria. (AU)


Subject(s)
Humans , Animals , Rats , Bone and Bones/diagnostic imaging , Osteology/trends , Musculoskeletal System/diagnostic imaging , Osteogenesis Imperfecta/diagnostic imaging , Osteoporosis/etiology , Osteoporosis/diagnostic imaging , Parathyroid Hormone/administration & dosage , Parathyroid Hormone/therapeutic use , Biomechanical Phenomena , Bone and Bones/anatomy & histology , Bone and Bones/metabolism , Bone Diseases, Metabolic/etiology , Bone Diseases, Metabolic/diagnostic imaging , Algorithms , Calcitonin/therapeutic use , Cholecalciferol/pharmacology , Human Growth Hormone/therapeutic use , Diphosphonates/pharmacology , Glucocorticoids/adverse effects , Glucocorticoids/pharmacology , Musculoskeletal System/anatomy & histology , Musculoskeletal System/metabolism
3.
J. appl. oral sci ; 25(5): 498-505, Sept.-Oct. 2017. tab, graf
Article in English | LILACS, BBO | ID: biblio-893658

ABSTRACT

Abstract Objective: This study aimed to evaluate the effects of continual intermittent administration of parathyroid hormone (PTH) on implant stability in the presence of osteoporosis, using rabbit models. Material and Methods: Fifteen female New Zealand white rabbits underwent ovariectomy and were administered glucocorticoids to induce osteoporosis, following which they were divided into three groups. The first group received intermittent subcutaneous PTH for 4 weeks until implant placement (PTH1), while the second and third groups received PTH (PTH2) and saline (control), respectively, for 4 weeks before and after implant placement. After intermittent administration of PTH or saline, titanium implants were inserted into the left femoral epiphyses of all animals, and the implant stability quotient (ISQ) was measured immediately after placement to assess the primary stability and at 2 and 4 weeks after implant placement to assess osseointegration. At 4 weeks after implant placement, histological and histomorphometric evaluations were conducted and the bone area around the implant socket was measured as a ratio of the total bone area to the total tissue area. Results: Regarding primary stability, the ISQ values for the PTH1 and PTH2 groups were significantly higher than those for the control group (p<0.05). Concerning osseointegration, the ISQ values at 2 and 4 weeks were significantly higher for the PTH2 group than for the PTH1 and control (p<0.05) groups. Histological assessments showed a thicker and more trabecular bone around the implant sockets in the PTH2 specimens than in the PTH1 and control specimens. The bone area around the implant socket was significantly greater in the PTH2 group than in the PTH1 and control groups (p<0.05). Conclusions: Our results suggest that continual intermittent PTH administration before and after dental implant placement is effective for the achievement of favorable stability and osseointegration in the presence of osteoporosis.


Subject(s)
Animals , Female , Rabbits , Osteoporosis/physiopathology , Parathyroid Hormone/administration & dosage , Dental Implants , Osseointegration/drug effects , Bone Density Conservation Agents/administration & dosage , Osteoporosis/pathology , Reference Values , Time Factors , Ovariectomy , Reproducibility of Results , Osseointegration/physiology , Treatment Outcome , Bone Remodeling/drug effects , Dental Implantation, Endosseous/methods , Disease Models, Animal , Femur/drug effects , Femur/pathology , Bone-Implant Interface/physiopathology , Resonance Frequency Analysis , Glucocorticoids , Injections, Subcutaneous
4.
West Indian med. j ; 61(9): 928-931, Dec. 2012.
Article in English | LILACS | ID: lil-694369

ABSTRACT

We report for the first time the case of a young man who developed both glucocorticoid resistance and resistance to parathyroid hormone. Treatment with high doses of dexamethasone together with administration of calcium and calcitriol resulted in a significant improvement in the patient's condition. In this paper, we discuss in detail diagnostic and treatment strategies used on the patient and the impact on the course and outcome of both disorders. We associate the development of both these disorders with a possible inherited defect in the signal pathways common to glucocorticoid and parathyroid hormone receptors.


Por primera vez se reporta el caso de un joven que desarrolló resistencia a glucocorticoides y resistencia a la hormona paratiroidea. El tratamiento con altas dosis de dexametasona, junto con la administración de calcio y calcitriol, trajo como resultado una mejoría significativa de la condición del paciente. En este papel, se analiza en detalle el diagnóstico así como las estrategias de tratamiento del paciente, y su impacto en el curso y resultado de ambos trastornos. Se concluye que el desarrollo de ambos trastornos se halla asociado a un posible defecto hereditario en las vías de transducción de señales comunes a los receptores de las hormonas glucocorticoides y las hormonas paratiroideas.


Subject(s)
Adult , Child , Humans , Male , Metabolism, Inborn Errors/genetics , Parathyroid Hormone/administration & dosage , Pseudohypoparathyroidism/diagnosis , Calcitriol/administration & dosage , Calcium Carbonate/administration & dosage , Dexamethasone/administration & dosage , Diagnosis, Differential , Drug Resistance , Drug Therapy, Combination , Phenotype , Pseudohypoparathyroidism/drug therapy , Pseudohypoparathyroidism/genetics , Receptors, Glucocorticoid/deficiency , Receptors, Glucocorticoid/genetics
5.
Yonsei Medical Journal ; : 166-172, 1999.
Article in English | WPRIM | ID: wpr-45257

ABSTRACT

To compare the effect of intermittent parathyroid hormone (PTH) treatment with that of estrogen treatment on epiphyseal growth in ovariectomized rats, 46 Sprague-Dawley female rats aged 9-10 weeks (about 200-220 g) were either ovariectomized or sham operated. From 6 weeks after ovariectomy (ovx), rats were daily injected with subcutaneous human recombinant PTH (1-84)-dosed 30 micrograms/kg (the low dose PTH-treated group) or 300 micrograms/kg (the high dose PTH-treated group), 17 beta-estradiol (the 17 beta-estradiol-treated group, 30 micrograms/kg) or vehicle (the ovx-alone group), 5 times a week for 4 weeks. The decalcified sections of the distal femoral epiphyseal plate were analyzed on light microscopy after H&E stain, and the lengths of the zones of proliferation, maturing and hypertrophic chondrocytes were measured. The length of the growth plate, the zone of proliferation and the zone of hypertrophic chondrocyte in the ovx-alone group were significantly shorter than those of the sham-operated group. The treatment of 17 beta-estradiol speeded up the differentiation of cells from proliferating chondrocytes to maturing and hypertrophic chondrocytes even though the length of the growth plate was comparable to that of the sham-operated group. Both low and high dose PTH treatments increased the length of the growth plate, and those lengths were comparable to that of the sham-operated group. The fractions of proliferating, maturing and hypertrophic zone in the low dose PTH-treated group were also comparable to those of the sham-operated group. However, high dose PTH treatment slowed down the differentiation of cells from proliferating chondrocytes to maturing and hypertrophic chondrocytes to a greater extent, and therefore the fraction of proliferating chondrocytes of the high dose PTH-treated group was larger than that of the low dose PTH-treated group (73.8 +/- 1.8 Vs 63.3 +/- 1.3%, p < 0.005). From these results, we showed that intermittent PTH treatment could promote linear growth in the ovariectomized growing rat. We propose that PTH may be an alternative drug candidate for promoting linear growth of long bones without the risk for early closure of the growth plate.


Subject(s)
Female , Humans , Rats , Animals , Bone Development/drug effects , Ovariectomy , Parathyroid Hormone/pharmacology , Parathyroid Hormone/administration & dosage , Rats, Sprague-Dawley , Recombinant Proteins
SELECTION OF CITATIONS
SEARCH DETAIL